This Sunday, April 11, the St. Vincent Hospital nurses will begin their sixth week on strike as part of their ongoing struggle to convince Dallas-based Tenet Healthcare to address a growing patient safety crisis at the Worcester-based hospital.
At least five people were killed by gunfire in election-related violence at two polling stations in India’s West Bengal state, police said Saturday. Security forces caused the majority of the casualties — four killed and four wounded — while trying to control a crowd outside a voting center in Cooch Behar district, said senior police officer Vishal Garg. Local elections in West Bengal, one of the most populous Indian states, are being held in eight phases.
A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15.
The National Weather Service issued a severe thunderstorm warning for Walker County, Alabama, on April 9.This video, shared by Twitter user @Nancee_Cain, shows hail falling in Walker County on Friday. Credit: @Nancee_Cain via Storyful
La Soufrière on Saint Vincent island spews ash 6 km into the air, as 16,000 people are evacuated.
Jordan Petaia produced back-to-back clutch plays as the Queensland Reds rallied from 12-0 down Saturday to beat the ACT Brumbies 24-22 and secure hosting rights for the Super Rugby Australia final. With his side trailing 22-13 and 18 minutes to play, Petaia, who scored the late winner when the sides last played, kicked to put the Brumbies in poor field position. Queensland flyhalf James O’Connor then kicked two penalty goals for the two-point margin of victory.
ST. PETERSBURG — The emails started coming months ago when the Lightning season was only just beginning. At first, it was just a trickle. Mostly curious, but a little frustrated. Readers wanting to know why they couldn’t get Lightning games from their TV provider. Eventually, the emails started to grow in number, and frustration turned to exasperation. By the time the Rays season began last ...
The Duke and Duchess of Sussex have broken their silence, sharing a short tribute to Prince Philip, who died Friday.
Obviously this was a particularly tasty apple tree - just ignore the windfalls and pick the fresh ones! So smart!
In this article we presented 10 best high-yield dividend stocks to buy according to billionaire George Soros. Click to skip our detailed discussion on Soros’ investment strategy and see 5 Best High-Yield Dividend Stocks to Buy According to Billionaire George Soros. George Soros is an American billionaire and hedge fund manager who founded Soros Fund Management […]
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting. The posters will be presented during the Preclinical Radiotherapeutics and Combination Immunotherapies sessions taking place today. The posters highlight the potential of Fusion's targeted alpha therapies (TATs) to enable delivery of an alpha particle emitting isotope (actinium-225) as both monotherapies and combination therapies across multiple tumor types.
Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company’s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021.
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company’s proprietary blood tests to advance precision oncology.
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented new clinical data on AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research (AACR) Annual Meeting from April 10 - 15, 2021. “The preclinical and translational data in conjunction with our updated clinical data with AGEN1181 alone or in combination with our PD-1, balstilimab, continue to strongly support and differentiate our next-generation CTLA-4 antibody,” said Steven O’Day, MD, Chief Medical Officer of Agenus. “AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies. Equally important, the safety data continues to show no immune mediated hypophysitis, pneumonitis, or hepatitis to date. Given the efficacy and favorable safety profile, we have expanded AGEN1181 into Phase 2 in colorectal cancer patients as a first step in our efforts to expand to additional important cancer indications.” In two separate presentations at AACR, Agenus showcased the optimal performance of AGEN1181 in relevant models. In addition, as the clinical data matures, additional responses as well as a conversion from a partial response to a complete response, have been observed. The new data announced today include the following clinical responses: New partial response in the first melanoma patient treated (monotherapy)New conversion to complete response in ovarian cancer patient (AGEN1181 plus balstilimab)Partial response in microsatellite stable (MSS) colorectal cancer patient (AGEN1181 plus balstilimab)Partial response in PD-L1(-) ovarian cancer patient (AGEN1181 plus balstilimab) Partial response in MSS colorectal cancer patient (AGEN1181 plus balstilimab)Complete response in PD-L1(-) MSS endometrial cancer patient (monotherapy)Complete response by PET in PD-L1(-) MSS endometrial cancer patient (AGEN1181 plus balstilimab) Presentation Details:E-poster presentations were made available on the conference platform on April 10 at 8:30am ET. Posters with accompanying audio will be available for viewing to meeting registrants until June 21. Session: PO.IM02.10 - Therapeutic Antibodies, Including Engineered AntibodiesPoster title: Fc-enhanced anti-CTLA-4 antibody, AGEN1181: New mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumorsAbstract number: 1878Presenting author: Antoine Tanne, PhD Session: PO.IM02.05 - Immune Monitoring / Clinical CorrelatesPoster title: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimabAbstract number: 1677Presenting author: Irina Shapiro, PhD In addition, Dr. Steven O’Day, Chief Medical Officer, Dr. Dhan Chand, Scientific Director, Head of Drug Discovery, and Dr. Jennifer Buell, President and COO, at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Saturday, April 10, 2021 at 10:30 a.m. ET. Registration for the webinar can be done in advance at https://williamblair.zoom.us/webinar/register/WN_4tTw7GEFQPC2qC4B3TzrfQ. A replay will be available after the call on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of AGEN1181 alone and in combination with other agents, as well as the potential to use such therapies in additional cancer indications. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917email@example.com
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the presentation by its collaborators in the Marc Ladanyi lab at Memorial Sloan Kettering (MSK) of further preclinical data on the specific inhibition of NRG1 fusion-induced tumorigenesis and signaling by seribantumab, a HER3 monoclonal antibody, at the American Association of Cancer Research Virtual Annual Meeting 2021. These data (Odintsov et al., 2021) in patient-derived xenograft (PDX) models of NRG1 fusion-positive pancreatic and cholangiocarcinoma build on earlier studies generated in lung and ovarian NRG1 fusion PDX models, recently published in Clinical Cancer Research, and further support the mechanistic rationale for the Phase 2 CRESTONE study for patients with solid tumors of any origin harboring an NRG1 gene fusion. The CRESTONE study is currently enrolling at sites across the United States.
The 2021 draft draws near for the Dallas Cowboys. Who will be chosen at No. 10? Which group in the draft has the most athletic ability?
Iran on Saturday began a 10-day lockdown amid a fourth wave of coronavirus infections, state TV reported, a worrisome trend after more than a year of the country battling the Middle East's worst outbreak. Iran's coronavirus task force, charged with determining virus restrictions, ordered most shops closed and offices restricted to one-third capacity in cities declared as “red-zones.” The capital Tehran and 250 other cities and towns across the country have been declared red zones.
Gun salutes were held across the United Kingdom on Saturday, April 10, to mark the death of Prince Philip at the age of 99.Batteries fired 41 rounds every minute from midday in cities including London, Edinburgh, Cardiff and Belfast, as well as Royal Navy warships, the Evening Standard reported.Video shared by the Tower of London shows a battery firing a salute alongside the River Thames with Tower Bridge seen in the distance. Credit: The Tower of London via Storyful
Results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant improvement in progression-free survival (PFS) with the investigational combination of Aliqopa® (copanlisib) and rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to the combination of rituximab and placebo. After a median follow-up of 19.2 months, patients treated with this combination had a median PFS of 21.5 months (95% CI 17.9, 33.0) versus 13.8 months in patients treated with rituximab and placebo (95% CI 10.2, 17.5), (HR=0.52, p=0.000002). No new safety signals were identified for Aliqopa in the combination arm of the study.1 The data will be presented in a Clinical Trials Plenary Session on April 10 at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 and simultaneously published in The Lancet Oncology.